Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya®) is recommended as an option for use within NHS Wales for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list / contract price is equivalent or lower than the WPAS price.